TICKERNERD
Menu
STXSSTXSHealthcare · Medical Instruments & Supplies

STXS Stock Forecast: Stereotaxis, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$1.33
+3.10% on the day

The 3 Wall Street analysts covering Stereotaxis, Inc. hold a median 12-month price target of $3 — +125.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$133.3M
Ticker Nerd rank
29 / 100
Median analyst target
$3.00
Analysts covering
3
Revenue$7.7M−12.8% y/y
Operating income−$4.6M
Net income−$4.5M
Free cash flow−$3.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.1%
1M
−2.2%
YTD
−42.2%
1Y
−52.5%
From 52W high
−62.7%
From 52W low
+5.6%
$1.26
$3.57
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STXS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stereotaxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
81
Size
73
Issuance
55
Accruals
42
Revisions
36
Volatility
33
Quality
32
Value
26
Momentum
9

Growth (81): Sales and profits are climbing, and climbing faster than before.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00$3.50Oct 25Jan 26Apr 26Jul 26STXSHigh $3.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.00Median $3.00High $3.00

The green dot is the last close — the median target sits +125.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2026CitizensMaintainsMarket Outperform—
12 Aug 2026TD CowenMaintainsBuy—
13 May 2026Piper SandlerReiteratesOverweight—
16 Dec 2025CitizensInitiatesMarket Outperform—
12 Nov 2025Roth CapitalReiteratesBuy—
5 Nov 2025Roth CapitalReinstatesBuy$4.00
5 Mar 2024Lake StreetMaintainsBuy—
5 Mar 2024Roth MKMReiteratesBuy—
10 Jan 2024Roth MKMInitiatesBuy—
6 Mar 2023B. Riley SecuritiesMaintainsBuy—
6 Mar 2023Lake StreetMaintainsBuy—
6 Mar 2023Piper SandlerMaintainsOverweight—
11 Nov 2022Cowen & Co.MaintainsOutperform—
2 Sept 2022B. Riley SecuritiesInitiatesBuy—
12 July 2022Aegis CapitalInitiatesBuy—
23 June 2022B. Riley SecuritiesInitiatesBuy—
5 Jan 2022Craig-HallumInitiatesBuy—
5 Jan 2022Loop CapitalInitiatesBuy—
26 May 2021Piper SandlerInitiatesOverweight—
8 Sept 2020Northland Capital MarketsInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STXS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STXS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Stereotaxis, Inc. returned −52.5% against +16.3% for the S&P 500, dividends included.

STXS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26STXSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Stereotaxis, Inc. (STXS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.3×

Cheaper than 90% of US stocks

Price / sales
4.4×

Cheaper than 28% of US stocks

Price / book
10.6×

Cheaper than 9% of US stocks

EV / EBITDA
−7.4×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
−12.8%

Higher than 14% of US stocks

Earnings growth (YoY)
−12.8%

Higher than 25% of US stocks

Gross margin
58.5%

Higher than 72% of US stocks

Operating margin
−59.6%

Higher than 16% of US stocks

Net margin
−74.2%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−184.3%

Higher than 8% of US stocks

Return on assets
−25.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Stereotaxis, Inc. (STXS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Stereotaxis, Inc. has a market value of $133.3M and an enterprise value of $133.2M.

  • Revenue in the twelve months to 30 June 2026: $30.1M. The latest quarter shrank 12.8% year on year.

  • Net income over the same four quarters: −$22.3M, a −74.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.24.

  • Free cash flow in the twelve months to 30 June 2026: −$15.5M.

  • Shares outstanding: 97.9M.

  • Trailing P/E: −5.3×; forward P/E: −8.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Stereotaxis, Inc. employs 131 people — $230K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

STXS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
STXSStereotaxis, Inc.$133.3M
29
KRMDKORU Medical Systems, Inc.$148.4M
95
ZJYLJin Medical International Ltd.$156.1M
17
PDEXPro-Dex, Inc.$231.6M
94
UTMDUtah Medical Products, Inc.$235.5M
79
OSUROraSure Technologies, Inc.$246.1M
89
DXRDaxor Corp.$66.8M
52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stereotaxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STXS news & analysis

Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026

GlobeNewsWire · 16 Sept 2026positive

Stereotaxis announced that its emerging digital, AI and automation capabilities, including Synchrony and SynX, will be featured at the Heart Rhythm Society's HRX 2026 conference. Additionally, the Stereotaxis CEO will join a main-stage panel on Autonomous EP Systems.

Why it matters — STXS watchers would care because showcasing its new digital and autonomous technologies at a major industry conference highlights the company's strategic focus on advancing its product pipeline and gaining visibility in the electrophysiology space.

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

GlobeNewsWire · 3 Sept 2026positive

Stereotaxis announced that the Electrophysiology team at the University of Szeged in Hungary treated over 70 patients using the Genesis Robotic Magnetic Navigation system just over a month after launching its robotic cardiology program, marking the program's strongest first month.

Why it matters — A strong early patient volume at a new European site indicates growing real-world adoption of Stereotaxis' Genesis system in clinical practice.

Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Stereotaxis, Inc. published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item is a record of the company's quarterly earnings call discussion.

Why it matters — STXS watchers would care because the transcript provides direct insight into management's commentary on the company's quarterly financial results and operations.

Stereotaxis Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026neutral

Stereotaxis reported second-quarter 2026 revenue of $7.7 million. Growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high, despite lower system revenue and continued supply constraints.

Why it matters — STXS watchers would care because the earnings report shows rising recurring revenue from the robotics portfolio despite ongoing system-revenue declines and supply constraints.

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 11 Aug 2026negative

Stereotaxis reported a second-quarter loss of $0.05 per share, wider than the Zacks Consensus Estimate loss of $0.03 and matching the year-ago loss, while also lagging revenue estimates.

Why it matters — The results missed analyst expectations on both earnings and revenue, which matters for investors monitoring Stereotaxis's quarterly financial performance.

FAQ

Frequently asked questions about STXS stock

What is the STXS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Stereotaxis, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STXS stock a buy right now?

Of the 3 analysts covering Stereotaxis, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stereotaxis, Inc. 29 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STXS?

As at 19 Sept 2026, Stereotaxis, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).

Will STXS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +125.6% from the last close, and Ticker Nerd's factor model ranks Stereotaxis, Inc. 29 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STXS stock forecast for 2030?

No analyst covering Stereotaxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.

How has STXS stock performed over the past year?

Stereotaxis, Inc. returned -52.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stereotaxis, Inc. do?

Stereotaxis Inc. is a medical technology company that develops robotic systems, instruments, and information solutions for interventional medicine.

What is the latest news on STXS?

The most recent item we track (GlobeNewsWire, 16 Sept 2026): "Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026". Stereotaxis announced that its emerging digital, AI and automation capabilities, including Synchrony and SynX, will be featured at the Heart Rhythm Society's HRX 2026 conference. Additionally, the Stereotaxis CEO will join a main-stage panel on Autonomous EP Systems.

Company

About Stereotaxis, Inc.

Stereotaxis Inc. is a medical technology company that develops robotic systems, instruments, and information solutions for interventional medicine. The company’s core offerings include robotic magnetic navigation platforms, such as Genesis RMN and GenesisX, which are designed to help physicians perform complex catheter-based procedures with computer-guided precision. Stereotaxis also provides the Odyssey Solution for procedure management and integrated information sharing, along with related imaging systems, disposables, and accessories used in cardiac and endovascular workflows. Its products are used primarily in electrophysiology and other minimally invasive interventions, supporting treatment of heart rhythm disorders and other vascular conditions. Based in St. Louis, Missouri, Stereotaxis focuses on combining robotics, imaging, and lab connectivity to improve clinical control and procedural efficiency in modern hospital interventional suites.

CEO Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. · 131 employees · United States · https://www.stereotaxis.com